$5.690
+0.154 (+2.71%)At close
SBC News
SBC Events
SBC Medical Group Starts Development of Biological Age Test
SBC Medical Group announced that it has commenced in-house development of a test designed to estimate an individual's biological age using DNA methylation analysis. Development will be led by the Company's AI and longevity-focused subsidiary, SBC AI Longevity Innovation. The initiative will leverage the regenerative medicine research and technology base established by Waqoo, a consolidated subsidiary of SBC Medical, and its subsidiary Cell Pro Japan. The test aims to provide insight into an individual's physical condition that chronological age alone cannot capture, offering a personal baseline for data-driven wellness and lifestyle adjustments.
SBC Medical Reports Q2 Revenue of $49M
Reports Q2 revenue $49M, consensus $45.45M. CEO Yoshiyuki Aikawa commented, "We believe our results this quarter clearly demonstrate that SBC Medical's growth story has entered a new phase. Having completed the structural reforms we undertook in 2025, we are now running multiple growth engines simultaneously. I am growing increasingly confident that this reacceleration is not a temporary phenomenon but reflects the strengthening of our underlying growth fundamentals...Looking ahead, we will deepen our multi-brand strategy in aesthetic dermatology domestically, while expanding our non-aesthetic business, which we position as our "second growth engine." Internationally, we plan to accelerate our global growth through our collaboration with OrangeTwist in the United States and our ASEAN expansion, anchored in Thailand. We are also preparing to enter the Longevity market, which we see as having enormous potential. With $184M in cash and cash equivalents on hand, we will continue to pursue disciplined investment toward our next growth phase. By pursuing sustained EPS growth and achieving fair equity valuation for our shares in the capital markets as two wheels of the same cart, we aim to deliver even greater value to all our stakeholders, including our shareholders. We look forward to what lies ahead for SBC Medical."
SBC Medical Reports Q1 Revenue of $43M, Below Expectations
Reports Q1 revenue $43M, consensus $41.66M. CEO Yoshiyuki Aikawa said, "For Q1 of FY26, SBC Medical reported revenue of $43 million, representing a 9% year-over-year decline. This decrease was primarily attributable to a strategic structural reform implemented in April 2025, involving a revision of the franchise fee structure. Excluding this structural change, the performance of our core business remained solid. In terms of profitability, our net income margin was 26%, and our EBITDA margin remained at a high level of 43%. Looking ahead, we will continue to promote our multi-brand strategy in the aesthetic dermatology field, expand our non-aesthetic medical business, and strengthen our operational foundation in overseas markets. In addition, we will pursue opportunities in the longevity market and further enhance our services through the utilization of AI, with the goal of building a sustainable and continuously growing healthcare platform."
Major Averages Drop Due to Strait of Hormuz Incidents
The major averages capped a down week with a sharp leg lower, as incidents in the Strait of Hormuz exacerbated traders' energy supply concerns despite President Trump saying he will hold off on further attacks on energy infrastructure in Iran. Oil prices are rising again, with Brent crude trading above $110 per barrel. Meanwhile, the Wall Street Journal reported that the Pentagon is considering sending another 10,000 ground troops to the Middle East, even as President Trump said he is pausing Iran "energy plant destruction" plans until April 6.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Carnivalreported, announced a new set of long-term targets, and announced an initial $2.5B share buyback program, but trimmed its annual profit target due to higher fuel costsUnityraisedand said it will sunset ironSource Ads NetworkAstraZenecasaid its COPD treatment tozorakimabin Phase 3 trialsNovartisbiotech company Excellergy for up to $2BEntergy Louisianaannounced awith Meta2. WALL STREET CALLS:TripAdvisorto Buy at BofA on "clearer catalyst path"Primo Brandsto Buy at JefferiesWix.comto Underweight at JPMorganBilibilito Buy at Citi following share price correctionUpstream Bioto In Line at Evercore ISI3. AROUND THE WEB:Citiis weighing acquiring a U.S. regional bank, Bloomberg reportsRivianhas completed winter testing of the VW ID. EVERY1, triggering a $1B investment from Volkswagen, TechCrunch reportsAmerican Airlinesis in discussions with SpaceX's Starlink and Amazonto overhaul its in-flight internet and entertainment, CNBC saysApplegranted out-of-cycle bonuses worth several hundred thousand dollars to iPhone hardware designers, as OpenAI and others poach its engineers, Bloomberg reportsCarlyleand KKRhave been selected by the U.S. Army to build two data centers on military bases that are estimated to cost $2B each, FT says4. MOVERS:Adma Biologicsincreases after responding to theKopingains afterBrown-Formanhigher afterwith Pernod RicardSatellogiclower after reporting a subcontract agreement withLithium Argentinafalls in New York after5. EARNINGS/GUIDANCE:Super League Enterprise, with EPS beating consensusAutolus, with CEO Christian Itin commenting, "Autolus had a strong first year of launch of AUCATZYL in the US"Legence, with EPS missing consensusSanuwave Healthand provided guidance for Q1 and FY26SBC Medical, with EPS beating consensusINDEXES:The Dow fell 793.47, or 1.73%, to 45,166.64, the Nasdaq lost 459.72, or 2.15%, to 20,948.36, and the S&P 500 declined 108.31, or 1.67%, to 6,368.85.
Major Averages Decline Amid Middle East Tensions
The major averages were broadly lower once again amid tensions in the Middle East, as incidents in the Strait of Hormuz exacerbated traders' energy supply concerns. Oil prices are rising again, with Brent crude trading above $110 per barrel. Meanwhile, the Wall Street Journal reported that the Pentagon is considering sending another 10,000 ground troops to the Middle East, even as President Trump said he is pausing Iran "energy plant destruction" plans until April 6.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Carnivalreported, announced a new set of long-term targets, and announced an initial $2.5B share buyback program, but trimmed its annual profit target due to higher fuel costsUnityraised itsand said it will sunset ironSource Ads NetworkAstraZenecasaid its COPD treatment tozorakimabin Phase 3 trialsNovartisbiotech company Excellergy for up to $2BEntergy Louisianaannounced awith Meta2. WALL STREET CALLS:TripAdvisorto Buy at BofA on "clearer catalyst path"Primo Brandsto Buy at JefferiesWix.comto Underweight at JPMorganBilibilito Buy at Citi following share price correctionUpstream Bioto In Line at Evercore ISI3. AROUND THE WEB:BASFhas sold a $290.6M stake in Harbour Energy through a share placing, WSJ reportsAmerican Airlinesis in discussions with SpaceX's Starlink and Amazonto overhaul its in-flight internet and entertainment, CNBC saysApplegranted out-of-cycle bonuses worth several hundred thousand dollars to iPhone hardware designers, as OpenAI and others poach its engineers, Bloomberg reportsCarlyleand KKRhave been selected by the U.S. Army to build two data centers on military bases that are estimated to cost $2B each, FT saysVolkwagen'spartnership with Rivianhas passed a key milestone, with winter tests of the first vehicles using the software successfully completed, Reuters reports4. MOVERS:Adma Biologicsincreases after responding to theby Culper ResearchKopingains afterBrown-Formanhigher afterwith Pernod RicardSatellogiclower after reporting awith Innovative Defense TechnologiesLithium Argentinafalls in New York after announcing a5. EARNINGS/GUIDANCE:Super League Enterprise, with EPS beating consensusAutolus, with CEO Christian Itin commenting, "Autolus had a strong first year of launch of AUCATZYL in the US"Legence, with EPS missing consensusSanuwave Healthand provided guidance for Q1 and FY26SBC Medical, with EPS beating consensusINDEXES:Near midday, the Dow was down 0.68%, or 313.71, to 45,646.40, the Nasdaq was down 1.06%, or 227.67, to 21,183.49, and the S&P 500 was down 0.68%, or 44.13, to 6,433.03.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.